Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.
|Articles|October 28, 2015
Valeant Responds to Drug Distribution Criticisms
Author(s)Randi Hernandez
October 28, 2015.
Advertisement
According to a recent report from Citron Research originally highlighted in the New York Times (Oct. 19, 2015), Valeant is using phantom drug distribution companies to manipulate distribution numbers to auditors. Philidor Rx Services came on the
BioPharm International's Randi Hernandez reports on
Advertisement
Related to this article
With 60% of Americans using AI health tools, patient advocates are encouraging collaborative use of AI alongside healthcare teams for better outcomes.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
AstraZeneca acquires Omniose, to bolster it's preclinical infectious disease programs.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward optimal results.
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site
2
Moderna Lays Out Oncology-Driven Growth Plan at 2026 Analyst Day
3
Pfizer and Blackstone Sign Co-Funding Deal for berobenatide
4
FDA Pauses Commissioner’s National Priority Voucher Program: Report
5